In what circumstances and how will latent tuberculosis infection be treated?;Dans quelles circonstances et comment traiter une infection tuberculeuse latente?

Revue des Maladies Respiratoires

Volumn 21, Issue 3 II, 2004, Pages

  Deschildre, A ^a   Poirier, C ^b   Cadranel, J ^c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Service de Protection Maternelle et Infantile (PMI)   (France)

^c HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

CARCINOMA; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; GASTRECTOMY; HEART TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JEJUNOILEAL BYPASS; KIDNEY FAILURE; LIVER TOXICITY; META ANALYSIS; RISK FACTOR; SILICOSIS; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 3242784008     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (53)

1. Avis du Conseil Supérieur d'Hygiène Publique de France - section maladies transmissibles, relatifau traitement de la tuberculose infection (séance du 14 mars 2003). http://www.sante.gouv.fr/htm/ dossiers/hygiene/tuberc_infect.pdf
2. Groupe de travail du Conseil Supérieur d'hygiène Publique de France: Recommandations pour la prévention et la prise en charge de la tuberculose en France. Rev Mal Respir 2003; 20: 7S7-7S106.
3. Ferebee SH: Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970; 17: 28-106.
4. Sutherland I: In: TSRU Progress Report. The ten year - incidence of clinical tuberculosis following « conversion » in 2250 individuals aged 14-19 years.; KNCV, The Hague 1968.
5. Starke JR, Jacobs RF, Jereb J: Resurgence of tuberculosis in children. J Pediatr 1992; 120: 839-55.
6. Comstock GW, Livesay VT, Woolpert SF: The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99: 131-8.
7. American Thoracic Society: Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: s221-47.
8. Gajalakshmi V, Peto R, Kanaka TS, Jha P: Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43000 adult male deaths and 35000 controls. Lancet 2003; 362: 507-15.
9. McKenna MT, McCray E, Onorato I: The epidemiology of tuberculosis among foreign - born persons in the United States, 1986 to 1993. N Engl J Med 1995; 332: 1071-6.
10. Rieder HI, Cauthen GM, Comstock GW, Snider DE Jr: Epidemiology of tuberculosis in the United States. EpidemiolRev 1989; 11: 79-98.
11. Bailey WC, Gerald LB, Kimerling ME, Redden D, Brook N, Bruce F, Tang S, Duncan S, Brooks CM, Dunlap NE: Predictive model to identify positive tuberculosis skin tests results during contact investigations. JAMA 2002; 287: 996-1002.
12. Gessner BD, Weiss NS, Nolan CM: Risk factors for pediatric tuberculosis infection and disease after household exposure to adult index cases in Alaska. J Pediatr 1998; 132: 509-13.
13. Madhi F, Fuhrman C, Monnet I, Atassi K, Poirier C, Housset B, Delacourt C: Transmission of tuberculosis from adults to children in a Paris suburb. Pediatr Pulmonol 2002; 34: 159-63.
14. Rodrigues LC, Diwan VK, Wheeler JG: Protective effect of BCG against tuberculous meningitis and miliaty tuberculosis: a meta-analysis. Int J Epidemiol 1993; 22: 1154-8.
15. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F: Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271: 698-702.
16. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, Fineberg HV: The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96: 29-35.
17. Menzies R, Vissandjee B: Effect of bacille Calmette-Guerin vaccination on tuberculin reactivity. Am Rev Respir Dis 1992; 145: 621-5.
18. Sarasin FP, Perrier A, Rochat T: Isoniazid preventive therapy for pulmonary tuberculosis sequelae: which patients up to which age? Tuber Lung Dis 1995; 76: 394-400.
19. Prise en charge des personnes infectées par le VIH. Paris: Médecine-Sciences Flammarion, 2002.
20. Joint Tuberculosis Committee of the British Thoracic Society: Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-48.
21. American Academy of Pediatrics, Committee on Infectious Diseases: Tuberculosis. In: Pickering LK, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, Il: American Academy of Pediatrics 2000: 593-613.
22. La tuberculose en France: comment arrêter l'épidémie actuelle? Texte du groupe de synthèse. Conférence d'experts sur la tuberculose. Med Mal Infect 1995; 25: 448-53.
23. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM: Isoniazid for preventing tuberculosis in non HIV infected persons [Cochrane Review]. In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
24. International Union Against Tuberculosis commitee on Prophylaxis: Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-64.
25. Snider DE, Jr, Caras GJ, Koplan JP: Preventive therapy with isoniazid: cost effectiveness of different durations of therapy. JAMA 1986; 255: 1579-85.
26. Comstock GW: How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3: 847-50.
27. Kopanoff DE, Snider DE, Jr, Caras GJ: Isoniazid-related hepatitis: a US Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117: 991-1001.
28. Nolan CM, Goldberg SV, Buskin SE: Hepatotoxicity associated with isoniazid preventive therapy: a 7 year survey from a public health tuberculosis clinic. JAMA 1999; 281: 1014-8.
29. LoBue PA, Moser KS: Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168: 443-7.
30. Hong Kong chest service/tuberculosis research centre, Madras/british medical research council: A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimen in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145: 36-41.
31. Villarino ME, Ridzon R, Weimuller PC, Elcock M: Rifampin preventive therapy for tuberculosis infection. Experience with 157 adolescents. Am J Respir Crit Care Med 1997; 155: 1735-8.
32. Ormerod LP: Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998; 169-71.
33. McNab BD, Marciniuk DD, Alvi RA, Tan L, Hoeppner VH: Twice weekly isoniazid and rifampin treatment of latent tuberculosis infection in Canadian plains aborigenes. Am J Respir Crit Care Med 2000; 167: 989-93.
34. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, Barry MA, O'Brien RJ: Rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 2000; 283: 1445-50.
35. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Geiter L, Johnson E, Huebner R, Boulos R, Chaisson RE: Randomized trial of isoniazid versus rifampin and pyrazinamide for the prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351: 786-92.
36. Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, Nyirenda O, Luo N, Pobee J, Elliott AM, McAdam KP, Porter JD: Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12: 2247-57.
37. Centers for Disease Control update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revision in American Thoracic Society/CDC recommendations - United States, 2001. MMWR Morb Mortal Wkly Rep 2001; 50: 733-5.
38. Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD: Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med 2003; 167: 824-7.
39. Chaisson RE, Armstrong J, Stafford J, Golub J, Bur S: Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners. JAMA 2002; 288: 165-6.
40. Centers for Disease Control and Prevention (CDC); American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52: 735-9.
41. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC: Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection [SCRIPT] Study Investigators. Short course Rifampin and Pyrazinamide compared with Isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137: 640-7.
42. McNeill L, Allen M, Estrada C, Cook P: Pyrazinamide and rifampin versus isoniazid for the treatment of latent tuberculosis. Improved completion rates but more hepatotoxicity. Chest 2003; 123: 102-6.
43. Magdorf K, Arizzi-Rusche AF, Geiter LJ, O'Brien Wahn U: Compliance and tolerance of new antitubercular short-term chemopreventive regimens in childhood-a pilot project. Pneumologie 1994; 48: 761-4.
44. Espinal MA, Reingold AL, Lavandera M: Effect of pregnancy on the risk of developing active tuberculosis. J Infect Dis 1996; 173: 488-91.
45. Ormerod P: Tuberculosis in pregnancy and the puerperium. Thorax 2001; 56: 494-9.
46. Wilkinson D: Drugs for preventing tuberculosis in HIV infected persons [Cochrane Review]. In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
47. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, Battegay M: Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 3: 501-7.
48. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, Mugerwa RD, Ellner JJ: A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337: 801-8.
49. de Pinho AM, Santoro-Lopes G, Harrison LH, Schechter M: Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. AIDS 2001; 15: 2129-35.
50. Casado JL, Moreno S, Fortun J, Antela A, Quereda C, Navas E, Moreno A, Dronda F: Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients. Clin Infect Dis 2002; 34: 386-9.
51. Ellard GA: Chemotherapy of tuberculosis for patients with renal impairment. Nephron 1993; 64: 169-81.
52. Cengiz K: Should tuberculosis prophylaxis be given for the chronically dialyzed patients. Nephron 2000; 86: 411-3.
53. Khan K, Muenning P, Behta M, Graff Zvin J: Global drug-resistance patterns and the management in immigrants to the United States. N Engl J Med 2002; 347: 1850-9.